FDA Approved Drugs by Medical Condition

Search by medical condition for drugs approved by the Food and Drug Administration (FDA) for sale in the United States. Select the letter below that corresponds to the first letter of the medical condition you are searching for and all approved drugs classified under that category will be listed below.

MAC Infection (Mycobacterium Avium Complex)

Zithromax (azithromycin) (by Pfizer), Approved June 1996
Treatment for Mycobacterium avium complex (MAC) in subjects with advanced HIV infection

Macular Degeneration

Eylea (aflibercept) (by Regeneron Pharmaceuticals), Approved November 2011
For the treatment of neovascular (wet) age-related macular degeneration

Male Hormonal Deficiencies/Abnormalities

Aveed (testosterone undecanoate) injection (by Endo Pharmaceuticals), Approved March 2014
For the treatment of hypogonadism

Bio-T-Gel (testosterone gel) (by Teva Pharmaceutical), Approved February 2012
For the treatment of hypogonadism

Natesto, (testosterone) nasal gel (by Trimel Pharmaceuticals), Approved May 2014
For the treatment of deficiency or absence of endogenous testosterone

Vogelxo (testosterone) gel (by Upsher-Smith), Approved June 2014
For males with a deficiency or absence of endogenous testosterone

Male Pattern Baldness

Propecia (by Merck), Approved December 1997
Treatment for male baldness

Malignant Melanoma

Intron A (Interferon alfa-2b, recombinant) (by Schering-Plough), Approved December 1995
An adjuvant treatment to surgery in subjects at high risk for systemic recurrence of malignant melanoma

Manic Disorders

Lithobid (Lithium Carbonate) (by Solvay Pharmaceuticals), Approved January 1996
Treatment for manic depression

Stavzor (valproic acid delayed release) (by Banner Pharmacaps), Approved July 2008
For the treatment of bipolar manic disorder, seizures and migraine headaches

Mantle Cell Lymphoma

Imbruvica (ibrutinib) (by Pharmacyclics), Approved November of 2013
For the treatment of mantle cell lymphoma

Revlimid (lenalidomide) (by Celgene), Approved December 2005
For the treatment of low- and intermediate-1-risk myelodysplastic syndromes

Revlimid (lenalidomide) (by Celgene), Approved June 2013
For the treatment of mantle cell lymphoma

Melanoma

Cotellic (cobimetinib) (by Genentech), Approved November 2015
For the treatment of BRAF V600E or V600K melanoma

Imlygic (talimogene laherparepvec) (by Amgen), Approved October 2015
For the treatment of unresectable recurrent melanoma

Keytruda (pembrolizumab) (by Merck), Approved September 2014
For the treatment of unresectable or metastatic melanoma

Mekinist (trametinib) (by GlaxoSmithKline), Approved May of 2013
For the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved December 2014
For the treatment of unresectable or metastatic melanoma

Sylatron (peginterferon alfa-2b) (by Merck), Approved April 2011
For the treatment of melanoma

Tafinlar (dabrafenib) (by GlaxoSmithKline), Approved May 2013
For the treatment of unresectable or metastatic melanoma with BRAF V600E mutation

Yervoy (ipilimumab) (by Bristol-Myers Squibb), Approved March 2011
For the treatment of metastatic melanoma

Zelboraf (vemurafenib) (by Roche), Approved August of 2011
For the treatment of BRAF + melanoma

Meningitis

Bexsero (Meningococcal Group B Vaccine) (by Novartis), Approved January 2015
For the treatment of invasive meningococcal disease caused by serogroup B

Menveo (meningitis vaccine) (by Novartis), Approved February 2010
For the active immunization to prevent invasive meningococcal disease

Merrem I.V. (meropenem) (by AstraZeneca), Approved June 1996
Treatment for intra-abdominal infections and bacterial meningitis

Menopause

Activella (Estradiol/Norethindrone Acetate) Tablets (by Novo Nordisk), Approved April 2000
Combination hormone replacement therapy for the prevention of osteoporosis and other symptoms associated w/postmenopause

Brisdelle (low-dose paroxetine mesylate) (by Noven Pharmaceuticals), Approved July 2013
For the treatment of vasomotor symptoms of menopause

Duavee (conjugated estrogens/bazedoxifene) (by Pfizer), Approved October 2013
For the treatment of vasomotor symptoms associated with menopause and postmenopausal osteoporosis

Elestrin (estradiol gel) (by BioSante), Approved December 2006
For the treatment of vasomotor symptoms associated with menopause

Esclim (by Fournier Research), Approved August 1998
Treatment for symptoms associated to Menopause

EstroGel (estradiol gel 0.06%) (by Solvay Pharmaceuticals), Approved April 2004
For the treatment of vasomotor symptoms and vulvar and vaginal atrophy associated with menopause

Evamist (estradiol) (by Vivus), Approved July 2007
For the treatment of moderate to severe vasomotor symptoms due to menopause

Femhrt Tablets (by Parke-Davis), October 15, 1999
Norethindrone acetate (1mg) and ethinyl estradiol tablets (5mcg)

FemPatch (by Parke-Davis), Approved December 1996
Treatment for menopausal symptoms

Intrarosa (prasterone vaginal insert) (by Endoceutics), Approved November 2016
For the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause

Osphena (ospemifene) (by Shionogi), Approved March 2013
For the treatment of dyspareunia and vulvar and vaginal atrophy due to menopause

Premarin (conjugated estrogens) (by Wyeth), Approved July of 2003
For the prevention of postmenopausal osteoporosis and treatment of vasomotor menopause symptoms

Vivelle (estradiol transdermal system) (by Ciba Pharmaceuticals), Approved March 1996
Treatment for moderate and severe vasomotor menopausal symptoms

Menstrual Disorders

Natazia (estradiol valerate and estradiol valerate/dienogest) (by Bayer), Approved March 2012
For the treatment of heavy menstrual bleeding

Menstruation

Natazia (estradiol valerate and estradiol valerate/dienogest) (by Bayer), Approved March 2012
For the treatment of heavy menstrual bleeding

Metabolic Disorders

Carbaglu (carglumic acid) (by Recordati), Approved March 2010
For the treatment of hyperammonemia

Cystaran (cysteamine hydrochloride) (by Sigma Tau Pharmaceuticals), Approved October 2012
For the treatment of corneal cystine crystal accumulation due to cystinosis

Elelyso (taliglucerase alfa) (by Pfizer), Approved May 2012
For the treatment of Gaucher disease

Procysbi (cysteamine bitartrate) (by Raptor Pharmaceuticals), Approved May 2013
For the management of nephropathic cystinosis

Ravicti (glycerol phenylbutyrate) (by Hyperion Therapeutics), Approved February 2013
For the treatment of pediatrics and adults with urea cycle disorders

Vimizim (elosulfase alfa) (by BioMarin), Approved February 2014
For the treatment of Mucopolysaccharidosis type IVA

Metastatic Cancer

Perjeta (pertuzumab) (by Genentech), Approved June 2012
For the first-line treatment of HER2+ metastatic breast cancer

Stivarga (regorafenib) (by Bayer HealthCare Pharmaceuticals), Approved September 2012
For the treatment of previously treated patients with metastatic colorectal cancer

Metastatic Melanoma

Cotellic (cobimetinib) (by Genentech), Approved November 2015
For the treatment of BRAF V600E or V600K melanoma

Erivedge (vismodegib) (by Genentech), Approved January 2012
For the treatment of basal cell carcinoma

Mekinist (trametinib) (by GlaxoSmithKline), Approved May of 2013
For the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations

Opdivo (nivolumab) (by Bristol-Myers Squibb), Approved December 2014
For the treatment of unresectable or metastatic melanoma

Proleukin (by Chiron), Approved January 1998
Treatment for metastatic melanoma

Tafinlar (dabrafenib) (by GlaxoSmithKline), Approved May 2013
For the treatment of unresectable or metastatic melanoma with BRAF V600E mutation

Migraine and Cluster Headaches

Amerge (by GlaxoSmithKline), Approved February 1998
Treatment for acute migraine

Axert (almotriptan malate) tablets (by Pharmacia & Upjohn), Approved May 2001
For the treatment of migraine attacks

Bayer Extra Strength Asprin (by Bayer), Approved October 2001
Oral treatment for mild to moderate migraine pain

Botox (onabotulinumtoxinA) (by Allergan), Approved October 2010
For the treatment of chronic migraine

Cambia (diclofenac potassium for oral solution) (by Kowa Pharmaceuticals), Approved June of 2009
For the treatment of migraine attacks

Depakote (divalproex sodium) (by Abbott Laboratories), Approved March 1996
Treatment for migraine headaches

Depakote ER (divalproex sodium) (by Abbott Laboratories), Approved August 2000
For the prophylaxis (prevention) of migraine headaches in adults

Excedrin Migraine (by Bristol-Myers Squibb), Approved January 1998
Treatment for mild to moderate migraine pain

Frova (frovatriptan succinate) (by Elan Pharmaceuticals), Approved November 2001
Tablets for the acute treatment of migraine attacks

Imitrex (sumatriptan) injection and tablets (by GlaxoSmithKline), Approved August 1997
Treatment for migraine headaches

Imitrex (sumatriptan) nasal spray (by GlaxoSmithKline), Approved November 1997
Treatment for migraine

Maxalt (by Merck), Approved June 1998
Acute treatment of migraine headache

Migranal (by Novartis), Approved December 1997
Treatment for migraine headaches

Onzetra Xsail (sumatriptan nasal powder) (by Avanir), Approved January 2016
For the treatment of migraine

Relpax (eletriptan hydrobromide) (by Pfizer), Approved December 2002
For the acute treatment of migraine headaches

Stavzor (valproic acid delayed release) (by Banner Pharmacaps), Approved July 2008
For the treatment of bipolar manic disorder, seizures and migraine headaches

Zomig (zolmitriptan) (by AstraZeneca), Approved February 2001
Orally disintegrating tablet for the treatment of acute migraine in adults

Zomig (zolmitriptan) (by AstraZeneca), Approved November 1997
Treatment for migraine

Mood Disorders

Zoloft (sertraline HCl) (by Pfizer), Approved May 2002
Oral tablets for the treatment of premenstrual dysphoric mood disorder (PMDD)

Multiple Myeloma

Darzalex (daratumumab) (by Janssen Biotech), Approved November 2015
For the treatment of multiple myeloma

Empliciti (elotuzumab) (by Bristol-Myers Squibb), Approved November 2015
For the treatment of patients with multiple myeloma who have received prior therapies

Farydak (panobinostat) (by Novartis), Approved February 2015
For the treatment of multiple myeloma

Kyprolis (carfilzomib) (by Onyx Pharmaceuticals), Approved July 2012
For the treatment of multiple myeloma

Ninlaro (ixazomib) (by Millennium Pharmaceuticals), Approved November 2015
For the treatment of multiple myeloma

Pomalyst (pomalidomide) (by Celgene), Approved February 2013
For the treatment of relapsed and refractory multiple myeloma

Multiple Sclerosis

Ampyra (dalfampridine) (by Acorda), Approved January 2010
For the improvement of walking in patients with multiple sclerosis

Aubagio (teriflunomide) (by Sanofi Aventis), Approved September 2012
For the treatment of multiple sclerosis

Avonex (Interferon Beta 1-A) (by Biogen IDEC), Recommended for Approval in December 1995
Treatment for multiple sclerosis

Copaxone (by Teva Pharmaceutical), Approved January 1997
Treatment for relapsing-remitting multiple sclerosis

Extavia (Interferon beta-l b) (by Novartis), Approved August of 2009
For the treatment of relapsing multiple sclerosis

Gilenya (fingolimod) (by Novartis), Approved September 2010
For the treatment of relapsing multiple sclerosis

Lemtrada (alemtuzumab) (by Genzyme), Approved November 2014
For the treatment of relapsing multiple sclerosis

Novantrone (mitoxantrone hydrochloride) (by Immunex), Approved October 2000
For reducing neurologic disability and/or the frequency of clinical relapses in patients with multiple sclerosis

Ocrevus (ocrelizumab) (by Genentech), Approved March 2017
For the treatment of multiple sclerosis

Plegridy (peginterferon beta-1a) (by Biogen IDEC.), Approved August 2014
For the treatment of relapsing multiple sclerosis

Rebif (interferon beta-1a) (by Serono Laboratories), Approved March 2002
Subcutaneous injection for the treatment of relapsing forms of multiple sclerosis

Tecfidera (dimethyl fumarate) (by Biogen Idec), Approved March 2013
For the treatment of relapsing multiple sclerosis

Tysabri (natalizumab) (by Elan Pharmaceuticals / Biogen Idec), Approved November 2004 -- Updated: Suspended February 2005--Updated: sBLA
For the treatment of relapsing forms of multiple sclerosis

Zinbryta (daclizumab) (by Biogen), Approved May 2016
For the treatment of relapsing multiple sclerosis

Muscle Pain

Amrix (cyclobenzaprine hydrochloride extended release) (by Cephalon), Approved February 2007
For the treatment of muscle spasm associated with acute, painful musculoskeletal conditions

Muscular Dystrophy

Emflaza (deflazacort) (by Marathon Pharmaceuticals), Approved February 2017
For the treatment of Duchenne muscular dystrophy

Exondys 51 (eteplirsen) (by Sarepta Therapeutics), Approved September 2016
For the treatment of Duchenne muscular dystrophy with mutated DMD gene amenable to exon 51 skipping

Mycosis Fungoides

Cresemba (isavuconazonium sulfate) (by Astellas), Approved March 2015
For the treatment of invasive aspergillosis and invasive mucormycosis

Myelofibrosis

Jakafi (ruxolitinib) (by Incyte), Approved November 2011
For the treatment of myelofibrosis

Myocardial Ischemia

Zontivity (vorapaxar) (by Merck), Approved May 2014
For the reduction of thrombotic cardiovascular events